Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer
Clinical trial NCT07616453 · RECRUITING
Trial details
- NCT number
- NCT07616453
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-06
- Primary completion
- 2028-05-05
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.